Sartar Therapeutics

Sartar Therapeutics

Sartar Therapeutics develops a new precision cancer treatment, SAR001, for soft tissue sarcomas specifically expressing the phosphodiesterase 3.

SAR001 is based on drug reformulation and repositioning of anagrelide, and has a long-acting profile that shows superior pharmacokinetic properties over oral administration, making it better tolerated and more convenient for use in therapy.

Sartar Therapeutics is lead by Katja Ivanisky and is based in Helsinki. The company joined NOME in 2021.